OUTSTANDING INVESTIGATOR

发现结构新颖和潜在的非常重要的癌症药物 从动物、植物和微生物来源将继续形成 杰出研究者补助金（Outstanding Investigator Grant） (OIG)美国国家癌症研究所（NCI） 提供 目前优秀的临床试验的最佳候选人 我们在海洋动植物中发现的抗癌物质 与spongistatin、dolastatin、halistatin和 头孢菌素，额外的重点将放在获得新成员 在进一步推进的同时阐明它们的结构 扩大苔藓抑素临床试验所需的研究知识 1. 将继续大力开展平行研究， 新化合物的分离、表征和结构测定， 从海洋动物、植物和 微生物的 OIG计划将用于分离和表征 这些新的抗癌药物从证实的活性提取物海洋 无脊椎动物和脊椎动物，海洋和陆地植物，以及海洋 微生物的 主要重点将放在海洋动植物上 产生具有显著活性水平的提取物的物种 在NCI的人类癌细胞系统，小鼠异种移植物中， 合适的、新的微生物和生化类型的预选方法。 只有那些最有希望产生新药的物种， 潜在的临床活动将由OIG基金进行。 其他这类 优先级较低的线索将在任何其他财政支持下进行 可能会有。 因为36年来一直致力于 为这项抗癌药物发现研究奠定基础， 许多极有前途的动物、微生物和植物 物种已经被发现，并将沿着新的 开发导致保持潜在有用的非常富有成效的输出 结构独特的物质。 与过去一样， OIG计划将极大地帮助DCT-NCI选择新的抗癌药物 候选药物并加速其临床试验的发展。 在 总的来说，整个更新OIG计划将集中在 新的抗癌药物的发现和非常迅速的发展， 美国国家癌症研究所旨在改善人类癌症的计划 治疗。

Discovery of structurally novel and potentially very important cancer drugs from animal, plant and microorganism sources will continue to form the sharply focused objective of the renewal Outstanding Investigator Grant (OIG) research for the National Cancer Institute (NCI). To provide the best candidates for eventual clinical trial among the current outstanding marine animal and plant anticancer substances we have discovered in collaboration with the spongistatins, dolastatins, halistatins and cephalostatins, additional emphasis will be placed on obtaining new members of these series and elucidating their structures while further advancing research knowledge necessary to the expanding clinical trials of bryostatin 1. Vigorous parallel research will continue to be strongly focused on the isolation, characterization and structural determination of new and potentially useful anticancer drugs from marine animals, plants and microorganisms. The OIG program would be used to isolate and characterize such new anticancer drugs from confirmed active extracts of marine invertebrates and vertebrates, marine and terrestrial plants, and marine microorganisms. The principal focus would be upon marine animal and plant species yielding extracts with an outstanding level of confirmed activity in the NCI's human cancer cell systems, murine xenografts and where appropriate, new microorganism and biochemical type preselection methods. Only those species that give maximum promise of yielding new drugs with potential clinical activity will be pursued with OIG funds. Other such leads of a lesser priority will be pursued with any other financial support that might be available. Because of 36 years devoted exclusively to constructing the foundation for this anticancer drug discovery research, a good number of exceedingly promising animal, microorganism and plant species have already been uncovered and will be used along with newly developed leads to maintain a very productive output of potentially useful antineoplastic substances of unique structure. As in the past the renewal OIG program will greatly assist the DCT-NCI in selecting new anticancer drug candidates and speeding their development toward clinical trial. In summary, the overall renewal OIG program will be sharply focused on the discovery and very rapid development of new anticancer drugs for the National Cancer Institute's programs directed at improving human cancer treatments.